Coronavirus

Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer

SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company…

3 months ago

EEG and EMG Devices Market to Grow by USD 793.5 Million (2024-2028) as Rising Neurological Conditions Drive Demand, AI Impact on Market Trends – Technavio Report

NEW YORK, Sept. 20, 2024 /PRNewswire/ -- Report with the AI impact on market trends- The global EEG and EMG devices…

3 months ago

Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union

Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age…

3 months ago

Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH

ALG-055009 dose groups met the primary endpoint with statistically significant reductions in liver fat at Week 12 as measured by…

3 months ago

Cidara Therapeutics Strengthens its Scientific Advisory Board with Infectious Disease Experts

SAN DIEGO, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform…

3 months ago

Aptevo Therapeutics Announces Closing of $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules

SEATTLE, WA / ACCESSWIRE / September 18, 2024 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing…

3 months ago

Aptevo Therapeutics Announces $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules

SEATTLE, WA / ACCESSWIRE / September 16, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing…

3 months ago

Aptevo Therapeutics and Alligator Bioscience Announce Data from Phase 1 ALG.APV-527 Monotherapy Trial Showing 60% of Evaluable Patients Achieved Stable Disease in Solid Tumor Study

Early Data Indicate Clinical Activity in Patients with Multiple Solid Tumor TypesProlonged stable disease lasting >11 months demonstrated in Breast…

3 months ago

Aptevo Therapeutics and Alligator Bioscience to Present Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at ESMO Congress 2024

SEATTLE WA and LUND, SWEDEN / ACCESSWIRE / September 13, 2024 / Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO) and Alligator Bioscience AB…

3 months ago

Sernova Announces New Positive Data from Phase I/II Trial Regarding Islet Survival and Function

Abundant, richly vascularized and functioning islets observed throughout all chambers of Sernova’s Cell Pouch more than 5 years after islet…

3 months ago